Cristian Caimmi1,2, Eugenia Bertoldo3,4, Anna Venturini3,4, Paola Caramaschi3,4, Luca Frulloni3,4, Rachele Ciccocioppo3,4, Sabrina Brunelli3,4, Luca Idolazzi3,4, Davide Gatti3,4, Maurizio Rossini3,4, Ombretta Viapiana3,4. 1. From the Rheumatology Unit, and the Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi, Verona, Italy. cristian.caimmi@gmail.com. 2. C. Caimmi, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; E. Bertoldo, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; A. Venturini, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; P. Caramaschi, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; L. Frulloni, MD, Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi; R. Ciccocioppo, MD, Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi; S. Brunelli, Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi; L. Idolazzi, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; D. Gatti, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; M. Rossini, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; O. Viapiana, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi. cristian.caimmi@gmail.com. 3. From the Rheumatology Unit, and the Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi, Verona, Italy. 4. C. Caimmi, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; E. Bertoldo, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; A. Venturini, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; P. Caramaschi, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; L. Frulloni, MD, Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi; R. Ciccocioppo, MD, Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi; S. Brunelli, Gastroenterology Unit, University of Verona, Policlinico G.B. Rossi; L. Idolazzi, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; D. Gatti, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; M. Rossini, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi; O. Viapiana, MD, Rheumatology Unit, University of Verona, Policlinico G.B. Rossi.
Abstract
OBJECTIVE: To evaluate the relationship between fecal calprotectin (FC) and interstitial lung disease (ILD) in systemic sclerosis (SSc). METHODS: The study enrolled 129 outpatients with SSc. Data about disease characteristics, in particular lung involvement, were collected and FC was measured. RESULTS: Patients with ILD (35, 27.1%) had higher values of FC (p < 0.001). In multivariate analysis, these variables were associated with increased risk of ILD: diffuse disease subset, higher modified Rodnan skin score, longer disease duration, higher severity scores, steroid treatment, and higher FC levels, while diverticulosis was protective. CONCLUSION: ILD is independently associated with increased FC levels in SSc.
OBJECTIVE: To evaluate the relationship between fecal calprotectin (FC) and interstitial lung disease (ILD) in systemic sclerosis (SSc). METHODS: The study enrolled 129 outpatients with SSc. Data about disease characteristics, in particular lung involvement, were collected and FC was measured. RESULTS:Patients with ILD (35, 27.1%) had higher values of FC (p < 0.001). In multivariate analysis, these variables were associated with increased risk of ILD: diffuse disease subset, higher modified Rodnan skin score, longer disease duration, higher severity scores, steroid treatment, and higher FC levels, while diverticulosis was protective. CONCLUSION:ILD is independently associated with increased FC levels in SSc.
Authors: Yun Gi Lee; Jisu Hong; Pureun Haneul Lee; Junehyuk Lee; Sung Woo Park; DoJin Kim; An Soo Jang Journal: J Korean Med Sci Date: 2020-11-09 Impact factor: 2.153